Orozco-Rico M

Language: Spanish
References: 21
Page: 44-49
PDF size: 520.19 Kb.

ABSTRACT

Acinetobacter species are Gram negative, strictly aerobic -fermenting cells and negative to oxidase coccobacilus. These species are found in nature mainly in soil, water, animals and human beings; especially A. baumannii is found in human skin, throat and rectus. It is an acquired colonizer in health care personnel. According to the CDC A. baumannii is the specie responsible for 80% of general infections for the general population in the United States. Also, reports have shown A. baumannii, A. calcoaceticus y A. liwoffii as other pathogen species. Since sometimes is hard to phenotypically differentiate the mentioned species, the term “Micrococcus calco-aceticus complex” is utilized when these three species cannot be differentiated. These microorganisms have the capacity to generate multiple resistance mechanisms to antibiotics, such as: modification and deactivation of antibiotic by hydrolysis mediated by enzymes (β-lactamases); the expression of porins on its membrane reduces the antibiotics permeability in outer membrane; expulsion of antibiotics by an efflux pump and modification of antibiotic´s target.

REFERENCES

1. 1.Munos SL, Weinstein. R A. Acinetobacter Infection. N Engl J Med 2008;358:1271-8.

2. 2.Rosenbaum P, Aureden K, Cloughessy M, Goss L, Kassai M, Streed SA, Patrick MR, Von Behren S, Wrigth MO. Guide to the Elimination of Multidrug-resistant Acinetobacter baumannii Transmission in Healthcare Settings. An APIC guide 2010

3. 3.Abbo A, Navon SV, Hammer OM, Krichali T, Siegman YI, Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 2005; 11(1).

4. 4.Borer A, Gilad J, Smolyakov R, Eskira S, Peled N, Porat N, et al. Cell Phones and Acinetobacter Transmission. Emerg Infect Dis 2005; 11(7).

5. 5.Yomayusa N, Suárez IC, Hernández P, Gaitán H, Altahona H, Ibáñez N, Hidalgo M, Moreno JE, Torrado E. Caracterización de un brote de infección por Acinetobacter baumannii en una unidad de cuidado crítico en Bogotá, Colombia. Asociación Colombiana de Infectología 2008; 12(1)

6. 6.Aguirre G, Mijangos JC, Zavala ML, Coronado H, Amaya G. Bacteremia por Acinetobacter baumannii en pacientes en estado crítico. Gac Méd Mex 2009; 145(1)

7. 7.Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J et al. Multidrug-resistant Acinetobacter Infection Mortality Rate and Length of Hospitalization. Emerg Infect Dis 2007; 13(1)

8. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L. Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii. Antimicrobs Agents Chemoter 2006; 50(9)

9. 9.Suárez CJ, Kattán JN, Guzmán A, Villegas MV. Mecanismos de Resistencia a Carbapenems en P. aeruginosa, Acinetobacter y Enterobacteriaceae. Asociación Colombiana de Infectología 2006; 10(2)

10. 10.Falagas ME, Koletsi PK, Bliziotis LA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006; 55, 1619-1629

11. 11.Naas T, Coignard B, Carbonne A, Blanckaert K, Bajolet O, Bernet C, (et col). VEB-1 Extended-Spectrum β-Lactamase–producing Acinetobacter baumannii, France. Emerg Infect Dis 2006; 12(8)

12. 12.Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Natu Rev Micrbiol 2007; 5: 939-955

13. 13.Jacoby GA, Munoz-Price LS. The New β-Lactamases. N Engl J Med 2005; 352(4)

14. 14.Bonomo RA, Szabo D. Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43

15. 15.Martínez P, Máttar S. Mutación en el gen gyrA de aislamientos hospitalarios de Acinetobacter baumannii en Montería, Colombia. Infectio 2010; 14(2)

16. 16.Cunha BA. Optimal Therapy for Multidrug-Resistant Acinetobacter baumannii. Emerg Infect Dis 2010; (16)1

17. 17.To the Editor: Polymyxin-Resistant Acinetobacter spp. Isolates: What Is Next? Emerg Infect Dis 2003; (9)8

18. 18.Ruzin A, Keeney D, Bradford PA. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus–Acinetobacter baumannii complex. JAC 2007; 59:1001-1004

19. 19.Cunha BA. Pharmacokinetic Considerations regarding Tigecycline for Multidrug-Resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii Urosepsis. JCM 2009; 47(5)

20. Gilbert DN, Moellering RC, Eliopoulos GM, Chambers HF, Saag MS. The Sanford Guide to Antimicrobial Therapy (40a edición) 2010, USA, editorial Antimicrobial Therapy

21. 21.Low Tigecycline Concentrations in the Cerebrospinal Fluid of a Neutropenic Patient with Inflamed Meninges. Antimicrobial Agents and Chemotherapy. 2011; 55: 449-450.